The Zacks Analyst Blog Highlights: Raytheon, The Boeing, Eli Lilly, Teva and
CHICAGO, July 11, 2012
CHICAGO, July 11, 2012 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Raytheon Company (NYSE:RTN), The
Boeing Company (NYSE:BA), Eli Lilly (NYSE:LLY), Teva (NYSE:TEVA) and Dr.
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday's Analyst Blog:
Raytheon Gets $636M Contract
Raytheon Company (NYSE:RTN) was awarded a $636 million development and
sustainment contract to provide the Exoatmospheric Kill Vehicle ("EKV") to The
Boeing Company (NYSE:BA). The EKV is part of the Ground-based Midcourse
Defense ("GMD") program, where Boeing is the prime contractor.
Under conditions of the contract, which extends through November 2018,
Raytheon will provide EKV development, fielding, testing, system engineering,
integration, configuration management, equipment manufacturing and
refurbishment, and operation and sustainment.
EKV represents the centerpiece for the Missile Defense Agency's GMD as the
intercept component of the Ground Based Interceptor, also known as GBI, which
is designed to engage high-speed ballistic missile warheads in space.
Raytheon is one of the best-positioned companies among the large-cap defense
players due to its non-platform-centric focus, as well as its strong order
bookings and order backlog of more than $34 billion at the end of the first
quarter of 2012.
Revenue and earnings growth continue to be driven by a strong presence in the
areas of Intelligence, Surveillance and Reconnaissance; air & missile defense
systems; border security; air traffic management; training and homeland
security; and cyber security. Also, its non-platform centric focus insulates
it from cancellation or deferral of any specific platform programs.
Looking forward, the company enjoys strong order bookings and order backlog,
an improving balance sheet, and growing cash flow, besides operational
improvements. Future growth will be driven by its focus on ISR unmanned
systems, training, cyber security, Standard Missile-6, Patriot, Zumwalt and
THAAD. The company presently retains a short-term Zacks #2 Rank (Buy).
This is, however, offset by apprehensions over future growth of the U.S.
defense budget, the fate of high-cost programs, risks related to key project
executions and order cancellations. Thus, over the longer run, we maintain our
long-term Neutral recommendation on the stock.
Based in Massachusetts, Raytheon Company is one of the largest aerospace and
defense companies in the U.S., with a diversified line of military products,
including missiles, radars, sensors, surveillance and reconnaissance
equipment, communication and information systems, naval systems, air traffic
control systems, and technical services.
Good News for Eli Lilly
Eli Lilly (NYSE:LLY) will now enjoy an additional six months of exclusivity in
the US for one of its lead products, Cymbalta. The US Food and Drug
Administration (FDA) recently granted pediatric exclusivity to Cymbalta, which
means that Cymbalta will be protected from generic competition in the US until
December 2013 instead of June 2013.
Eli Lilly, however, pointed out that Cymbalta is not approved for use in
children and the company does not intend to seek approval for this patient
Cymbalta, one of the key products in Eli Lilly's pipeline, is approved for a
wide range of indications including the treatment of major depressive disorder
and generalized anxiety disorder and the management of diabetic peripheral
neuropathic pain and fibromyalgia. Cymbalta is also approved for the
management of chronic musculoskeletal pain in people with chronic
osteoarthritis pain or chronic low back pain.
Cymbalta, which accounted for 17.1% of Eli Lilly's total revenues in 2011,
posted total sales of $4.16 billion in 2011. US sales were $3.2 billion in
Cymbalta continues to perform well with first quarter 2012 sales in the US
coming in at $857.6 million. Given Cymbalta's current performance, the
additional six month exclusivity period could result in sales of at least $1.6
billion in the US.
This bodes well for Eli Lilly, which currently faces a major patent cliff.
Zyprexa, which posted sales of $4.62 billion in 2011, lost exclusivity in the
EU and US in late 2011. Companies like Teva (NYSE:TEVA) and Dr. Reddy's
(NYSE:RDY) have launched their generic version of the product and we expect a
rapid erosion in Zyprexa sales. In fact, Eli Lilly expects Zyprexa sales to
fall by more than $3 billion in 2012. First quarter 2012 Zyprexa sales fell
56% to $562.7 million.
We currently have a Neutral recommendation on Eli Lilly, which carries a Zacks
#3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.